April 3, 2019 08:09 AM EDTUpdated May 28, 12:01 PM
Deals

As Spark share­hold­ers balk, FTC holdup helps de­lay Roche's $4.3B buy­out

Amber Tong

Roche is hav­ing a bit of a hic­cup in clos­ing its $4.3 bil­lion buy­out of Spark af­ter a heat­ed bid­ding war, caus­ing the phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Re­searchers make case against Gilead in HIV prod­uct hop­ping fight

Up­dat­ed: Zealand part­ners with Roche on its amylin ana­log in a deal worth up to $5.3B

Viking Ther­a­peu­tics taps Cor­den­Phar­ma to man­u­fac­ture its obe­si­ty drugs

Mallinck­rodt and En­do ex­plor­ing a $7B merg­er — re­port

Ex­clu­sive: FDA blocks drug and de­vice re­view­ers from tak­ing HH­S' buy­out of­fer

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times